细胞分裂周期相关蛋白激酶7和微小染色体维持蛋白2的表达与弥漫大B细胞淋巴瘤患者预后的关系

摘要

目的 探讨弥漫大B细胞淋巴瘤(DLBCL)组织中细胞分裂周期相关蛋白激酶7( Cdc7)和微小染色体维持蛋白2(MCM2)的表达以及与患者预后的关系.方法 收集经病理证实的60例DLBCL患者的临床资料,应用荧光定量PCR法测定患者外周血和骨髓中Cdc7和MCM2基因的表达,分析Cdc7和MCM2基因表达与患者预后的关系.结果 外周血Cdc7高表达组和低表达组患者的2年生存率分别为38.3％和65.4％ (P =0.001),骨髓Cdc7高表达组和低表达组患者的2年生存率分别为37.2％和75.5％ (P =0.032),外周血MCM2高表达组和低表达组患者的2年生存率分别为44.0％和68.2％ (P =0.025),骨髓MCM2高表达组和低表达组患者的2年生存率分别为39.0％和63.4％ (P =0.007).外周血和骨髓中Cdc7和MCM2基因高表达是DLBCL患者的预后不良因素.结论 Cdc7和MCM2的表达与传统预后指标相结合可以准确预测DLBCL患者的预后,靶向调控Cdc7和MCM2通路可能成为治疗难治性DLBCL患者的新途径.%Objective The aim of this study was to assess the expression of cell division cycle 7 (Cdc 7) kinase and minichromosome maintenance protein 2 (MCM2) in diffuse large B cell lymphoma (DLBCL) and explore their relationship with prognosis of DLBCL patients.Methods Clinical data of 60 DLBCL patients treated in our hospital from 2008.1 to 2010.1 were collected.The expression levels of Cdc7 and MCM2 in peripheral blood and bone marrow were determined by real-time PCR.A statistical analysis was carried out to evaluate their association with prognosis in DLBCL patients.Results The 2-year survival rate of patients with high expression of peripheral blood Cdc7 was 38.3％ and those with low expression 65.4％ (P =0.001 ).The 2-year survival rate of patients with high expression of bone marrow Cdc7 was 37.2％ and those with low expression was 75.5％ ( P =0.032).The 2-year survival rate of patients with high expression of MCM2 in peripheral blood was 44.0％ and those with low expression was 68.2％ (P =0.025 ).The 2-year survival rate of patients with high expression of MCM2 in bone marrow was 39.0％ and those with low expression was 63.4％ ( P =0.007).A poor disease specific survival was observed in DLBCL patients with high level expression of Cdc7 and MCM2.Conclusions Cdc7 and MCM2 expression can be used to assess tumor proliferation and may be useful as an additional marker in combination with conventional markers in prediction of the outcome of DLBCL patients.Moreover,the Cdc7 and MCM2 signal pathway might be useful as a new approach in the treatment of refractory DLBCL lymphoma patients.